Objective: To assess the efficacy and the mechanism of action of α-interferon (α-IFN) in the treatment of HIV-related thrombocytopenia. Methods: Thirteen HIV-positive subjects [nine men and four women with severe thrombocytopenia (platelets, ≤30 x 109/I)] were treated with α-IFN2b alone at a dose of 3 x 106 U three times a week for 5 weeks. Haematological parameters, platelet kinetic and bone-marrow myeloid progenitor cultures [megakaryocyte colony-forming units (CFU-MK); granulocyte macrophage CFU (CFU-GM) and erythroid burst-forming units (BFU-E)I were evaluated before and after treatment in responsive subjects. Results: Seven out of 13 subjects showed a partial response (platelets, 50-149 x 109/I) after α-IFN 2b therapy. Platelet survival as evaluated by 111In-oxine significantly increased, while platelet turnover showed a slight but not statistically significant increase after treatment. The growth of bone-marrow myeloid progenitor cells decreased after α-IFN 2b therapy, again without statistical significance. Conclusion α-IFN 2b may increase the platelet count in HIV-positive subjects with severe symptomatic thrombocytopenia by prolonging platelet survival. The immunomodulatory and antiviral action of this drug may be responsible for prolonged platelet survival.
Recombinant α-interferon 2b in the treatment of HIV-related thrombocytopenia / Vianelli N.; Catani L.; Gugliotta L.; Belmonte M.M.; Cascione L.; Colangeli V.; Ricchi E.; Mazza P.; Mazzucconi M.G.; Chistolini A.; Bagnara G.P.; Tura S.. - In: AIDS. - ISSN 0269-9370. - STAMPA. - 7:6(1993), pp. 823-827. [10.1097/00002030-199306000-00010]
Recombinant α-interferon 2b in the treatment of HIV-related thrombocytopenia
Catani L.;
1993
Abstract
Objective: To assess the efficacy and the mechanism of action of α-interferon (α-IFN) in the treatment of HIV-related thrombocytopenia. Methods: Thirteen HIV-positive subjects [nine men and four women with severe thrombocytopenia (platelets, ≤30 x 109/I)] were treated with α-IFN2b alone at a dose of 3 x 106 U three times a week for 5 weeks. Haematological parameters, platelet kinetic and bone-marrow myeloid progenitor cultures [megakaryocyte colony-forming units (CFU-MK); granulocyte macrophage CFU (CFU-GM) and erythroid burst-forming units (BFU-E)I were evaluated before and after treatment in responsive subjects. Results: Seven out of 13 subjects showed a partial response (platelets, 50-149 x 109/I) after α-IFN 2b therapy. Platelet survival as evaluated by 111In-oxine significantly increased, while platelet turnover showed a slight but not statistically significant increase after treatment. The growth of bone-marrow myeloid progenitor cells decreased after α-IFN 2b therapy, again without statistical significance. Conclusion α-IFN 2b may increase the platelet count in HIV-positive subjects with severe symptomatic thrombocytopenia by prolonging platelet survival. The immunomodulatory and antiviral action of this drug may be responsible for prolonged platelet survival.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
